Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

Kristina
request-745706-de648021@whatdotheyknow.com

MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

www.gov.uk/mhra

11th May 2021

Dear Kristina,

Our Ref: FOI 21/392

Thank you for your email dated 10th April 2021, where you asked for the following information:

"exactly how many people have died within 28 days of receiving a covid 19 vaccination in the United Kingdom."

Suspected adverse drug reactions can be reported via the Yellow Card scheme at any time after the side effect has occurred. Additionally, the time frame from when the patient received the vaccine to experiencing a suspected side effect is not always provided by the reporter. We review all reports of death regardless of the time to onset from receiving a medicine or vaccine. Our routine ADR summary publication provides information on all reports received associated with COVID-19 vaccines including fatalities.
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions

We follow-up all fatalities where permission has been provided to do so for further information including post-mortem details if available. As with any serious suspected ADR, reports with a fatal outcome are fully evaluated by the MHRA, to consider whether the vaccine (or medicine) may have caused the event, or whether the event and fatal outcome were likely to be purely coincidental and due to underlying illness.

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team
Vigilance and Risk Management of Medicines Division

Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

For information on the reproduction or re-use of MHRA information, please visit
https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF